In addition, pretreatment with RSL3 (a GPX4 inhibitor) decreases the number of persister cells in HER2‐amplified BC BT474 parental cells, which have survived from lapatinib (a HER2 inhibitor) treatment, indicating the presence of GPX4‐sensitive cells in the persister cells.60 Here, GPX4 is linked to breast cancer.